Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Cadrenal Therapeutics (Nasdaq: CVKD) has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit, scheduled for January 13, 2025. The company's Chairman and CEO, Quang X. Pham, will engage in a virtual fireside chat at 10:30 a.m. Eastern time.
Cadrenal Therapeutics specializes in developing tecarfarin, a novel oral vitamin K antagonist (VKA) currently in advanced clinical development. This therapeutic is designed to provide a superior and safer anticoagulation alternative for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
The virtual event will be accessible through the conference website, with replay options available. Interested investors can request one-on-one meetings through Lytham Partners representatives.
Cadrenal Therapeutics (Nasdaq: CVKD) ha annunciato la sua partecipazione al prossimo Lytham Partners 2025 Investor Healthcare Summit, in programma per il 13 gennaio 2025. Il presidente e CEO dell'azienda, Quang X. Pham, parteciperà a una chat online alle 10:30 ora orientale.
Cadrenal Therapeutics è specializzata nello sviluppo di tecarfarin, un nuovo antagonista orale della vitamina K (VKA) attualmente in fase avanzata di sviluppo clinico. Questa terapia è progettata per fornire una alternativa anticoagulante sicura e superiore per i pazienti dipendenti da warfarin con dispositivi cardiaci impiantati o condizioni cardiovascolari rare.
L'evento virtuale sarà accessibile tramite il sito web della conferenza, con opzioni di riproduzione disponibili. Gli investitori interessati possono richiedere incontri individuali attraverso i rappresentanti di Lytham Partners.
Cadrenal Therapeutics (Nasdaq: CVKD) ha anunciado su participación en el próximo Lytham Partners 2025 Investor Healthcare Summit, programado para el 13 de enero de 2025. El presidente y CEO de la empresa, Quang X. Pham, participará en una charla virtual a las 10:30 a.m. hora del Este.
Cadrenal Therapeutics se especializa en el desarrollo de tecarfarin, un nuevo antagonista oral de la vitamina K (VKA) que se encuentra actualmente en desarrollo clínico avanzado. Esta terapia está diseñada para proporcionar una alternativa anticoagulante superior y más segura para los pacientes dependientes de warfarina que tienen dispositivos cardiacos implantados o condiciones cardiovasculares raras.
El evento virtual será accesible a través del sitio web de la conferencia, con opciones de repetición disponibles. Los inversores interesados pueden solicitar reuniones individuales a través de representantes de Lytham Partners.
카드레날 제약 (Nasdaq: CVKD)는 2025년 1월 13일로 예정된 리담 파트너스 2025 투자자 헬스케어 서밋에 참여할 것이라고 발표했습니다. 회사의 회장 겸 CEO인 Quang X. Pham은 동부 표준시 기준 오전 10시 30분에 가상 화상 대화에 참석할 것입니다.
카드레날 제약은 현재 고급 임상 개발 중인 테카르파린이라는 새로운 경구용 비타민 K 길항제를 개발하는 데 주력하고 있습니다. 이 치료법은 심장 장치가 이식된 유와 핀으로, 드문 심혈관 질환을 앓고 있는 환자에게 보다 안전하고 우수한 항응고 대안을 제공하도록 설계되었습니다.
가상 이벤트는 회의 웹사이트를 통해 접근 가능하며, 재생 옵션도 제공됩니다. 관심 있는 투자자는 리담 파트너스 대표를 통해 개별 회의를 요청할 수 있습니다.
Cadrenal Therapeutics (Nasdaq: CVKD) a annoncé sa participation au prochain Lytham Partners 2025 Investor Healthcare Summit, prévu pour le 13 janvier 2025. Le président et PDG de l'entreprise, Quang X. Pham, participera à une discussion virtuelle à 10h30 heure de l'Est.
Cadrenal Therapeutics se spécialise dans le développement de tecarfarin, un nouvel anticoagulant oral à base de vitamine K (VKA) actuellement en développement clinique avancé. Ce traitement est conçu pour offrir une alternative anticoagulante supérieure et plus sûre pour les patients dépendants de la warfarine ayant des dispositifs cardiaques implantés ou des affections cardiovasculaires rares.
L'événement virtuel sera accessible via le site de la conférence, avec des options de rediffusion disponibles. Les investisseurs intéressés peuvent demander des réunions individuelles par l'intermédiaire des représentants de Lytham Partners.
Cadrenal Therapeutics (Nasdaq: CVKD) hat seine Teilnahme am bevorstehenden Lytham Partners 2025 Investor Healthcare Summit bekannt gegeben, der für den 13. Januar 2025 geplant ist. Der Vorsitzende und CEO des Unternehmens, Quang X. Pham, wird um 10:30 Uhr Eastern Time an einem virtuellen Gespräch teilnehmen.
Cadrenal Therapeutics hat sich auf die Entwicklung von tecarfarin spezialisiert, einem neuartigen oralen Vitamin-K-Antagonisten (VKA), der sich derzeit in der fortgeschrittenen klinischen Entwicklung befindet. Diese Therapie soll eine überlegene und sicherere Antikoagulationsalternative für von Warfarin abhängige Patienten mit implantierten Herzgeräten oder seltenen Herz-Kreislauf-Erkrankungen bieten.
Die virtuelle Veranstaltung wird über die Konferenz-Website zugänglich sein, mit verfügbaren Wiederholungsoptionen. Interessierte Investoren können über Vertreter von Lytham Partners Einzelgespräche anfordern.
- None.
- None.
Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
The fireside chat will take place at 10:30 a.m. Eastern time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/health2025/ or directly at https://lythampartners.com/health2025/cvkd. A replay of the fireside chat will also be available through same links.
1x1 investor meetings will be available after the event upon request by contacting your Lytham representative at 1x1@lythampartners.com.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company in advanced clinical development focused on developing tecarfarin, a novel oral and reversible anticoagulant for the prevention of heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions.
Tecarfarin is a vitamin K antagonist (VKA) potentially representing the first new therapeutic innovation in 70 years in VKA anticoagulation. Tecarfarin is designed to be a superior and safer chronic oral anticoagulant therapy compared to warfarin for patients with implanted cardiac devices or rare cardiovascular conditions.
Cadrenal Therapeutics’ drug candidate, tecarfarin, is expected to enter its pivotal Phase 3 trial during 2025. The Company’s clinical program for tecarfarin is supported by extensive data demonstrating the molecule’s potential as an alternative to warfarin, with safety data indicating fewer adverse events such as strokes, heart attacks, bleeds, and deaths in comparison with warfarin. The FDA granted tecarfarin orphan drug designation (ODD) for heart failure patients with implanted left ventricular assist devices (LVADs) as well as both ODD and Fast Track designation for end-stage kidney disease (ESKD) patients with atrial fibrillation (AFib).
For more information, please visit www.cadrenal.com and connect with the company on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109166162/en/
Corporate and Investor Relations
Lisa DeScenza
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com
Media
Andrew Korda
LaVoieHealthScience
(617) 865-0043
akorda@lavoiehealthscience.com
Source: Cadrenal Therapeutics, Inc.
FAQ
When is Cadrenal Therapeutics (CVKD) presenting at the Lytham Partners Healthcare Summit?
What is tecarfarin and how is it different from warfarin?
How can investors access CVKD's presentation at the Lytham Partners Healthcare Summit?
How can investors arrange 1x1 meetings with CVKD management?
What is the primary focus of Cadrenal Therapeutics' (CVKD) drug development?
